Minapharm Pharmaceuticals (CAI:MIPH) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CAI:MIPH Minapharm Pharmaceuticals CAI:MIPH
41 GF Score
Price E£760.00
GF Value E£363.03
Valuation Significantly Overvalued
! 10 Warning Signs
View Full Analysis

What is Minapharm Pharmaceuticals FFO per Share?

FFO per Share only applies to REITs.

CAI:MIPH
41GF Score
Minapharm Pharmaceuticals CAI:MIPH
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Minapharm Pharmaceuticals (CAI:MIPH) Overvalued in 2026?

Based on GuruFocus' analysis, Minapharm Pharmaceuticals stock appears to be overvalued. The current stock price of E£760.00 is trading 109.3% above its estimated GF Value™ of E£363.03. GuruFocus considers Minapharm Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for CAI:MIPH:

  • FFO per Share:
  • GF Value™: E£363.03 vs. price of E£760.00 (109.3% above fair value)
  • GF Score™: 41/100 with 10 warning signs

No single metric tells the full story. See the CAI:MIPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Minapharm Pharmaceuticals Business Description

Address El-Bardissi Street, 2T Takseem Asmaa Fahmy Street, Heliopolis, Cairo, EGY
Minapharm Pharmaceuticals is a company whose purpose is to produce medicines and chemicals. medical supplies. cosmetics, veterinary medicines, dental supplies, and the production of dietary supplements and herbal medicines. It produces drugs for many segments such as biogenetics, orthopedic, ophthalmology, miscellaneous, dermatology, gastroenterology, cardiology, and uro-gynaecology lines.
41GF Score

Get the complete analysis for CAI:MIPH

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

E£760.00
Price
E£363.03
GF Value